First seen Jul 1, 2026 · Updated 3h ago · 2 source items
Chatter ahead of a pivotal oral GLP-1 readout is accelerating across biotech and investor accounts, with efficacy expectations converging on a narrow range.
An oral formulation with injectable-class efficacy would reset the obesity-market size assumptions embedded in current valuations.
High expected market impact (relevance 94/100). Most exposed: $LLY, $NVO.
Consensus for the oral GLP-1 readout has tightened to 13-15% weight loss. Anything at the top end and the injectable-vs-oral debate is over.
♥ 2.9K⇄ 840💬 260👁 415.0K
Obesity-drug race turns to oral formulations
Investor attention is concentrating on upcoming oral GLP-1 data as the next competitive inflection.
15h ago · BioPharma Ledger
Obesity-drug race turns to oral formulations
6h ago · X
Consensus for the oral GLP-1 readout has tightened to 13-15% weight loss. Anything at the top end and the injectable-vs-oral debate is over.
High confidence (78/100), supported mainly by velocity (86) and limited mainly by source credibility (66).
Tickers
Companies
Agencies
Topics
Pre-readout consensus ranges are frequently wrong in both directions; binary event risk is extreme.